Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Spyre Therapeutics (SYRE) EBT Margin (2016 - 2023)

Spyre Therapeutics (SYRE) has disclosed EBT Margin for 7 consecutive years, with 31551.45% as the latest value for Q2 2023.

  • For the quarter ending Q2 2023, EBT Margin fell 2798121.0% year-over-year to 31551.45%, compared with a TTM value of 52933.58% through Mar 2024, down 4624061.0%, and an annual FY2023 reading of 38241.08%, down 3463649.0% over the prior year.
  • EBT Margin was 31551.45% for Q2 2023 at Spyre Therapeutics, down from 9322.22% in the prior quarter.
  • Across five years, EBT Margin topped out at 56.15% in Q2 2021 and bottomed at 31551.45% in Q2 2023.
  • Average EBT Margin over 3 years is 7643.17%, with a median of 3570.24% recorded in 2022.
  • The sharpest move saw EBT Margin tumbled -351409bps in 2022, then plummeted -2798121bps in 2023.
  • Year by year, EBT Margin stood at 560.46% in 2021, then plummeted by -1892bps to 11165.48% in 2022, then plummeted by -183bps to 31551.45% in 2023.
  • Business Quant data shows EBT Margin for SYRE at 31551.45% in Q2 2023, 9322.22% in Q1 2023, and 11165.48% in Q4 2022.